“Neurofibromatosis 2 Pipeline” report has been recently added to Delveinsight
About Neurofibromatosis 2
Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas/vestibular schwannomas).
Download free sample copy of Neurofibromatosis 2 pipeline report- https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight
Neurofibromatosis 2 Diagnosis
The diagnosis of NF2 is confirmed by a thorough clinical evaluation and specialized testing (i.e., CT scan, magnetic resonance imaging (MRI), pneumoencephalogram, or arteriogram are very rarely used nowadays). Molecular genetic testing for mutations in the NF2 gene is available for most affected individuals who have a positive family history.
Neurofibromatosis 2 Causes
NF2 is caused by a mutation in the NF2 gene. The NF2 gene regulates (encodes for) the production of a protein known as merlin/schwannomin that plays a role in suppressing the development of certain tumors (tumor suppressor). According to investigators, merlin/schwannomin is related to a class of proteins (ezrin-radixin-moesin proteins) that serve to link the internal, supportive system within a cell (cytoskeleton) to proteins in cell membranes. Several different mutations of the NF2 gene have been identified in individuals with the disorder (e.g., deletions, nonsense and frameshift mutations).
Neurofibromatosis 2 Treatment
The treatment of vestibular (acoustic) neuromas associated with NF2 is the surgical removal of the tumors, when possible. The surgical procedure that is performed is based upon the size and precise location of the tumors. Radiation therapy may be considered for some individuals with this disorder, especially those who are not candidates for surgery. The VEGF inhibitor bevacizumab may also be considered to treat rapidly growing schwannomas but is very expensive.
Neurofibromatosis 2 Key Players
Neurofibromatosis 2 Emerging Drugs
Neurofibromatosis 2 Pipeline Development Activities
The report provides insights into:
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Neurofibromatosis 2: Report Highlights
Following is the table of content of Neurofibromatosis 2 pipeline report
1. Report Introduction
2. Neurofibromatosis 2
3. Neurofibromatosis 2 Current Treatment Patterns
4. Neurofibromatosis 2 – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Neurofibromatosis 2 Late Stage Products (Phase-III)
7. Neurofibromatosis 2 Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neurofibromatosis 2 Discontinued Products
13. Neurofibromatosis 2 Product Profiles
14. Neurofibromatosis 2 Key Companies
15. Neurofibromatosis 2 Key Products
16. Dormant and Discontinued Products
17. Neurofibromatosis 2 Unmet Needs
18. Neurofibromatosis 2 Future Perspectives
19. Neurofibromatosis 2 Analyst Review
20. Appendix
21. Report Methodology
Neurofibromatosis 2: Key Questions
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/